IL7R activation is well documented in hematological malignancies such as acute lymphoblastic leukemia, where it drives pro-survival and proliferation pathways (notably via JAK/STAT, MAPK/ERK, and PI3K/AKT/mTOR signaling) [37, 50–54]. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.